Clinical Trial Update: Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase I study of gemcitabine, sorafenib and radiotherapy in patients with unresectable pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Nexavar (Sorafenib)

Snippet

Sponsor: Indiana University School of Medicine | Conditions: Pancreatic Cancer, Adenocarcinoma of the Pancreas | Phase 1 | Status: COMPLETED